Sustained Wnt/β-catenin signaling rescues high glucose induction of transforming growth factor-β1-mediated renal fibrosis

American Journal of the Medical Sciences

Volumn 344, Issue 5, 2012, Pages 374-382

  Ho, Cheng ^a   Lee, Pei Hsien ^a,b   Hsu, Yung Chien ^a   Wang, Feng Sheng ^a,b   Huang, Yu Ting ^a   Lin, Chun Liang ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Fibrosis; Mesangial cells; TGF 1; Wnt catenin

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 4',6 DIAMIDINO 2 PHENYLINDOLE; BETA CATENIN; FIBRONECTIN; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; PROTEIN C JUN; TRANSFORMING GROWTH FACTOR BETA1; WNT PROTEIN; WNT4 PROTEIN; WNT5A PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC TRANSFECTION; GLOMERULUS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION;

EID: 84871564249     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31824369c5     Document Type: Article

References (33)

1. Incidence and prevalence of ESRD. United States Renal Data System. Am J Kidney Dis 1998;32:S38-49.
2. Steffes MW, Mauer SM. Diabetic glomerulopathy in man and experimental animal models. Int Rev Exp Pathol 1984;26:147-75.
3. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999;56:1627-37.
4. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998;14:59-88.
5. Akiyama T. Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 2000;11:273-82.
6. Plisov S, Tsang M, Shi G, et al. Cited 1 is a bifunctional transcriptional cofactor that regulates early nephronic patterning. J Am Soc Nephrol 2005;16:1632-44.
7. Park JS, Valerius MT, McMahon AP. Wnt/{beta}-catenin signaling regulates nephron induction during mouse kidney development. Development 2007;134:2533-9.
8. Surendran K, Schiavi S, Hruska KA. Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 2005;16:2373-84.
9. Surendran K, Simon TC, Liapis H, et al. Matrilysin (MMP-7) expression in renal tubular damage: association with Wnt4. Kidney Int 2004;65:2212-22.
10. Lin CL, Wang JY, Huang YT, et al. Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 2006;17:2812-20.
11. Nishita M, Hashimoto MK, Ogata S, et al. Interaction between Wnt and TGF-beta signalling pathways during formation of Spemann's organizer. Nature 2000;403:781-5.
12. Letamendia A, Labbe E, Attisano L. Transcriptional regulation by Smads: crosstalk between the TGF-beta and Wnt pathways. J Bone Joint Surg Am 2001;83:S31-9.
13. De Langhe SP, Sala FG, Del Moral, et al. Dickkopf-1 (DKK1) reveals that fibronectin is a major target of Wnt signaling in branching morphogenesis of the mouse embryonic lung. Dev Biol 2005;277:316-31.
14. Kanda S, Miyata Y, Kanetake H. T-cell factor-4-dependent upregulation of fibronectin is involved in fibroblast growth factor-2-induced tube formation by endothelial cells. J Cell Biochem 2005;94: 835-47.
15. Kemler R, Hierholzer A, Kanzler B, et al. Stabilization of betacatenin in the mouse zygote leads to premature epithelial-mesenchymal transition in the epiblast. Development 2004;131:5817-24.
16. Kim L, Kimmel AR. GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 2000;10:508-14.
17. Doble BW, Woodgett Jr. GSK-3: tricks of the trade for a multi tasking kinase. J Cell Sci 2003; 116:1175-86.
18. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-76.
19. Henriksen EJ, Teachey MK, Taylor ZC, et al. Isomer-specific actions of conjugated linoleic acid on muscle glucose transport in the obese Zucker rat. Am J Physiol Endocrinol Metab 2003;285:E98-105.
20. Savory J, Ghribi O, Herman MM. Is amyloid beta-peptide neurotoxic or neuroprotective and what is its role in the binding of metal ions? Neurobiol Aging 2002;23:1089-92.
21. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001;65:391-426.
22. Lin CL, Wang FS, Kuo YR, et al. Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int 2006;69:1593-600.
23. Farago M, Dominguez I, Landesman-Bollag E, et al. Kinase-inactive glycogen synthase kinase 3b promotes Wnt signaling and mammary tumorigenesis. Cancer Res 2005;65:5792-801.
24. Edlund S, Lee SY, Grimsby S, et al. Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol 2005;25:1475-88.
25. Kloth JN, Fleuren GJ, Oosting J, et al. Substantial changes in gene expression of Wnt, MAPK and TNFalpha pathways induced by TGF- betal in cervical cancer cell lines. Carcinogenesis 2005;26:1493-502.
26. Zhou S, Eid K, Glowacki J. Cooperation between TGF-beta and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. J Bone Miner Res 2004; 19:463-70.
27. Tuli R, Tuli S, Nandi S, et al. Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk. J Biol Chem 2003;278:41227-36.
28. Hwang SG, Yu SS, Lee SW, et al. Wnt-3a regulates chondrocyte differentiation via c-Jun/AP-1 pathway. FEBS Lett 2005;579: 4837-42.
29. Nateri AS, Spencer-Dene B, Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 2005; 437:281-5.
30. Gradl D, Kuhl M, Wedlich D. The Wnt/Wg signal transducer betacatenin controls fibronectin expression. Mol Cell Biol 1999;19:5576-87.
31. Wagman AS, Johnson KW, Bussiere DE. Discovery and develop ment of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004;10:1105-37.
32. Ring DB, Johnson KW, Henriksen EJ, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003;52:588-95.
33. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004;25:471-80.